📝 Bharat Parenterals Ltd — results explained
Quarter ended June 2026 (Q1 FY27)
Bharat Parenterals Ltd reported revenue of ₹94 crore for the quarter ended June 2026 (Q1 FY27), down 19.2% from ₹116 crore in the same quarter last year, and down 5.9% sequentially over the March 2026 quarter.
The company reported a net loss of ₹4 crore, against a net loss of ₹1 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-5.17.
Operating profit stood at ₹9 crore — an operating margin (OPM) of 9.1%, compared with 11.9% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Bharat Parenterals Ltd posted revenue of ₹345 crore, a growth of 1.5% over FY25, with a net loss of ₹27 crore.
On a trailing-twelve-month (TTM) basis, revenue stands at ₹323 crore with a net loss of ₹30 crore.
Valuation snapshot
At the current price of ₹1,517.05, 541096 has a market capitalisation of ₹1,062 crore.
Within the Pharmaceuticals industry, it is the 9th-largest of the 82 companies we track by market value.
Shareholding pattern
As of Jun 2026, promoters held 67.20%, foreign institutional investors (FIIs) 0.11%, domestic institutional investors (DIIs) 1.38%, public shareholders 31.31% of Bharat Parenterals Ltd.